Aligos Trims Staff to Hone Focus on Early Clinical Programs in NASH, Covid-19
The Aligos Therapeutics pipeline reprioritization comes after clinical trial setbacks to two hepatitis B drug candidates led the biotech to end both programs. Still intact is a Merck research collaboration focused on developing NASH therapies.